Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
News about Atara Biotherapeutics, Inc. (NASDAQ: ATRA) centers on its development of allogeneic T-cell immunotherapies and the regulatory and business milestones associated with its Epstein-Barr virus (EBV)-specific platform. Atara describes itself as a leader in T-cell immunotherapy, focused on off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, with headquarters in Southern California. Much of the company’s recent news flow has highlighted progress and challenges around tabelecleucel (tab-cel or EBVALLO), its EBV-specific T-cell therapy for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Investors following ATRA news can expect updates on FDA interactions, including Biologics License Application (BLA) submissions, Priority Review status, Prescription Drug User Fee Act (PDUFA) target action dates, and Complete Response Letters. Releases have detailed how Atara and its partner Pierre Fabre Laboratories addressed Good Manufacturing Practice (GMP) observations, transferred the tabelecleucel IND and BLA, and responded to evolving FDA positions on the adequacy of the pivotal ALLELE study for accelerated approval.
Company news also covers financial results and corporate restructuring, such as quarterly earnings releases, changes in research and development and general and administrative expenses, workforce reductions, lease amendments, and the impact of tabelecleucel-related milestone payments and commercialization revenue. In addition, Atara has issued updates on its strategic alternatives review, describing potential transactions it may consider to maximize shareholder value.
For readers tracking ATRA, this news stream provides insight into Atara’s clinical and regulatory trajectory, its partnership with Pierre Fabre Laboratories on tabelecleucel/EBVALLO, and the company’s evolving cost structure and strategic direction. Regularly reviewing these updates can help contextualize movements in ATRA stock and developments in the EBV-focused cell therapy space.
Atara Biotherapeutics (ATRA) reported its Q2 2021 financial results, highlighting significant regulatory progress for tab-cel® and anticipated approvals in 2022. The company expects to submit a Biologics License Application for tab-cel® by Q1 2022 and aims for EU Marketing Authorization Application submission in November 2021. Financially, Atara recorded a net loss of $83.8 million, or $0.91 per share, with cash reserves at $373.4 million, projected to fund operations into 2023. Increased R&D expenses were noted, reflecting investments in pipeline programs.
Atara Biotherapeutics (Nasdaq: ATRA) announces the appointment of Ameet Mallik to its Board of Directors. Mr. Mallik, an expert in biotechnology with over 25 years of experience, has a successful history of bringing oncology therapeutics to market. His leadership is expected to enhance Atara's efforts to commercialize its lead product, tab-cel®, anticipated for approval in 2022. Mallik's expertise spans commercial operations at Novartis and Rafael Holdings, positioning him to drive Atara's mission of transforming the lives of patients with serious diseases.
Atara Biotherapeutics (Nasdaq:ATRA) announced the grant of 110,626 restricted stock units and stock options for 69,744 shares to newly hired employees. These awards were approved by the Compensation Committee under the 2018 Inducement Plan, effective August 2, 2021. The restricted stock units will vest over four years, with the first 25% vesting after one year. The stock options also vest over four years, starting with 25% after the first anniversary. This action complies with Nasdaq Listing Rule 5635(c)(4).
Atara Biotherapeutics announced it will release its second quarter 2021 financial results post-market on August 9, 2021. Following the release, a live conference call will be held at 4:30 p.m. EDT to discuss financial results and provide corporate updates. Participants can join by calling 877-407-8291 for domestic callers or 201-689-8345 for international. The company aims to provide transformative therapies using its EBV T-cell platform to address serious diseases.
Atara Biotherapeutics (Nasdaq: ATRA) has granted 124,580 restricted stock units and options to purchase 99,585 shares to newly hired employees as part of its 2018 Inducement Plan. The stock options have a ten-year term with an exercise price of $16.05 per share, aligning with the company's closing stock price on July 1, 2021. The awards support Atara’s strategy to attract talent in the competitive T-cell immunotherapy field, aimed at developing therapies for cancer and autoimmune diseases.
Atara Biotherapeutics (Nasdaq: ATRA) has joined the Rare Disease Company Coalition, focusing on developing treatments for rare diseases like EBV-driven post-transplant lymphoproliferative disease. This alliance of life sciences companies aims to inform policymakers about the unique challenges in rare disease therapies and advocate for supportive policies to enhance innovation and access to treatments. Atara is committed to addressing the urgent needs of patients with rare blood cancers and is actively engaging with industry peers to advance effective healthcare initiatives.
Atara Biotherapeutics (Nasdaq: ATRA) recently presented long-term overall survival (OS) data for its therapy, tabelecleucel (tab-cel), aimed at patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD). Presented at the American Transplant Congress 2021, the analysis from three clinical studies shows a 1-year and 2-year OS rate of 100% and 87.5%, respectively, in certain patient groups. Tab-cel was well tolerated, with no significant safety issues reported, addressing a critical need in treating this high-mortality condition.
Atara Biotherapeutics (Nasdaq: ATRA) announced the granting of 140,861 restricted stock units and stock options for 124,966 shares to newly hired employees, approved by the Compensation Committee. The awards are part of the 2018 Inducement Plan, with vesting periods spanning four years. The stock options have a ten-year term and an exercise price of $13.97, equal to the closing price on June 1, 2021. This information is provided in compliance with Nasdaq Listing Rule 5635(c)(4), highlighting Atara's commitment to attracting talent as it advances its T-cell immunotherapy platform.
Atara Biotherapeutics (Nasdaq: ATRA) has granted inducement awards to Cokey Nguyen, the new Senior VP and Chief Scientific Officer. The awards include 115,440 restricted stock units and stock options for 174,249 shares, part of the 2018 Inducement Plan, dated May 10, 2021. The restricted stock units will vest over four years, while stock options will have a ten-year term at an exercise price of $13.24 per share. This move adheres to Nasdaq Listing Rule 5635(c)(4), aimed at attracting key talent for the company's ongoing development in T-cell immunotherapy.
Atara Biotherapeutics (Nasdaq: ATRA) announced participation in the Cowen Virtual Oncology Innovation Summit on May 20, 2021, featuring CEO Pascal Touchon and CMO AJ Joshi. The discussion will focus on Atara's innovative T-cell immunotherapy platform aimed at treating serious conditions such as solid tumors and autoimmune diseases. A live webcast will be available on Atara's website, with an archived replay accessible for 30 days post-event. Atara is leading in T-cell immunotherapy development with a robust pipeline, including treatments for Epstein-Barr virus-driven diseases.